Fluanxol/Fluanxol Depot

Tab: Schizophrenia & allied psychoses eg, hallucinations, delusions & thought disturbances along w/ apathy, lack of energy, lowered mood & w/drawal. Inj: Schizophrenia & other related psychoses.

Tab Adult Schizophrenia & allied psychoses Individualized dose. Initially 3-15 mg daily divided in 2 or 3 daily doses. May increase to 40 mg daily if necessary. Maintenance dose: 5-20 mg daily usually given as a single dose in the morning. Inj Adult 20 mg/mL, usually as 1-2 mL via IM inj & an interval of 1-4 wk. If needed >2 mL, divide between 2 inj site or 100 mg/mL about 1 mL (may vary between 0.5 mL & 4 mL), & the interval of 1-4 wk. If needed >2 mL, divide between 2 inj sites.

May be taken with or without food.

Hypersensitivity. Tab: Circulatory collapse, depressed level of consciousness due to any cause (eg, intoxication w/ alcohol, barbiturates or opiates), coma. Inj: Diminished consciousness.

Pregnancy & lactation. Childn. Tab: Hypersensitivity. NMS; discontinue treatment if symptoms develop. Patients w/ organic brain syndrome, convulsion & advanced hepatic disease; susceptible individuals (w/ hypokalemia, hypomagnesia or genetic predisposition) & w/ history of CV disorders, recent acute MI, uncompensated heart failure or cardiac arrhythmia; risk factors for stroke. Not recommended for excitable or overactive patients in doses up to 25 mg/day. May modify insulin & glucose responses in diabetic patients. Carefully monitor patients on long-term therapy particularly on high doses & evaluate periodically. May cause QT prolongation increasing the risk of malignant arrhythmias. Avoid concomitant treatment w/ other antipsychotics. Closely monitor patients for depression & increased risk of suicidal thoughts, self-harm & suicide; major depressive disorder; history of suicide-related events, or those exhibiting significant degree of suicidal ideation prior to start of treatment. VTE. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not for the treatment of dementia-related behavioural disturbances. May impair general attention & conc which affects ability to drive or operate machinery. Childn. Elderly (increased risk of CV events & death). Inj: Liver problem; history of convulsion or fits, & CV disorders; diabetes; organic brain syndrome; risk factors of stroke; hypokalemia or hypomagnesia; other antipsychotic medicine; increased excitement or overactive; family history of blood clots; treated for cancer. Do not drive or use any tool or machines if feeling drowsy & dizzy. Adolescents.

Somnolence, akathisia, hyperkinesia, hypokinesia; dry mouth. Tachycardia, palpitations; tremor, dystonia, dizziness, headache; accommodation disorder, abnormal vision; dyspnoea; salivary hypersecretion, constipation, vomiting, dyspepsia, diarrhea; micturition disorder, urinary retention; hyperhidrosis, pruritus; myalgia; increased appetite, increased wt; asthenia, fatigue; insomnia, depression, nervousness, agitation, decreased libido.

May enhance sedative effect of alcohol & effects of barbiturates & other CNS depressants. May increase or reduce the effect of antihypertensive drugs. Reduced antihypertensive effect of guanethidine & similar acting compd. Increased risk of neurotoxicity w/ lithium. Inhibit metabolism of TCAs. May reduce effect of levodopa & adrenergic drugs. Increases risk of extrapyramidal symptoms w/ metoclopramide & piperazine. Increased QT interval w/ class Ia & III antiarrhythmics (eg, quinidine, amiodarone, sotalol, dofetilide), antipsychotics (eg, thioridazine), macrolides (eg, erythromycin), antihistamines (eg, terfenadine, astemizole), quinolone antibiotics (eg, gatifloxacin, moxifloxacin). May increase risk of QT prolongation & malignant arrhythmias w/ drugs known to cause electrolyte disturbances eg, thiazide diuretics & drugs known to increased plasma conc of flupentixol.

Antipsychotics

N05AF01 - flupentixol ; Belongs to the class of thioxanthene derivatives antipsychotics.

S